Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.

Journal of translational medicine - 30 Dec 2011

Fučíková Jitka, Rožková Daniela, Ulčová Hana, Budinský Vít, Sochorová Klára, Pokorná Kateřina, Bartůňková Jiřina, Špíšek Radek

Abstract excerpt

BACKGROUND: For clinical applications, dendritic cells (DCs) need to be generated using GMP-approved reagents. In this study, we tested the characteristics of DCs generated in two clinical grade culture media and activated by three maturation stimuli, Poly I: C, LPS and the mixture of proinflammatory cytokines in order to identify the optimal combination of culture media and activation stimulus for the clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Culture Media

Share to Dendritic Cells

Share to Epitopes

Share to Immunotherapy

Share to Poly I-C

Share to T-Lymphocytes, Regulatory

Source

Open in PubMed Open full text

Identifiers

PMID: 22208910
DOI: 10.1186/1479-5876-9-223
PMCID: PMC3259090

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.PMID 22208910Read ↗

Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.Semantic proximity Read ↗

Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application.Semantic proximity Read ↗

Comparison of two different protocols for the induction of maturation of human dendritic cells in vitro.Semantic proximity Read ↗

Clinical-scale generation of dendritic cells in a closed system.Semantic proximity Read ↗

Phenotypical and functional characterization of clinical-grade dendritic cells.Semantic proximity Read ↗

Dendritic cells in vivo and in vitro.Semantic proximity Read ↗

Comparative study of clinical grade human tolerogenic dendritic cells.Semantic proximity Read ↗

Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails.Semantic proximity Read ↗

Tumor necrosis factor-α promotes survival and phenotypic maturation of poly(I:C)-treated dendritic cells but impairs their Th1 and Th17 polarizing capability.Semantic proximity Read ↗

Feeder-free generation of functional dendritic cells from human pluripotent stem cellsSemantic proximity Read ↗

Generation of mouse and human dendritic cells in vitro.Semantic proximity Read ↗

Maturation induction of human peripheral blood mononuclear cell-derived dendritic cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.